Phacilitate | Advanced therapies opportunities in Europe
Phacilitate Leaders Europe
17th – 18th September 2019
Royal Lancaster London
It can be easy to overlook Europe ‘s CGT significance given the dominant market position of the US and huge growth potential in Asia.
However, developments in healthcare infrastructure, huge clinical trial activity and advancing payer and reimbursement models put Europe at the forefront of the global advanced therapies industry.
To put this into context, Phacilitate have compiled this handy infographic which gives loads of insights into current projects and opportunities available in Europe and Israel today. Take a glance here. Many of the developers featured in the infographic will be taking part in Phacilitate Leaders Europe in September.
The vision for the Phacilitate event this year is advocating opportunities for the development of advanced therapies in Europe. We'd really like you to join us there next month, to meet with potential new partners, and hear European success stories directly from those whose therapies have made it to market.
Whether you're an established player in the EU, or are looking to enter into the European market, there is opportunity for everyone. Join us for 2 days, 2 networking receptions, 3 content tracks, 2 partnering lunches and plenty of opportunity for 1-2-1 partnership meetings.
We asked the event manager, Kim Barnes, why she is excited for Phacilitate Leaders Europe and these were her top 4 reasons:
- I can’t wait to hear from Kite, Novartis and bluebird bio who will be discussing the challenges of having an approved product in the European market. We are promoting Europe as a hub for advanced therapies, and who better to hear from than the 3 companies who have success stories in the region
- I love looking around the room and seeing our attendees making new connections. This year we have added in some great networking events including an evening with Dr Claire Roddie, one of the clinicians treating patients with CAR-T therapy in the UK. These events give our attendees a chance to relax, learn and make new friends which is so important for advancing the field
- We have 56 investors confirmed for the event so far, and I am excited to match these with biotechs needing investment at our biotech/investor lunch. I love connecting people!
- Finally, I cannot wait to launch our new MATCH program for our early-stage biotech community. This program aims to help these biotechs design their commercialisation strategy by matching them with the right supplier for their needs
For more information about networking, the agenda, and speakers, please visit the event website.
To sign up for the conference please click here.